TITLE

Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide

AUTHOR(S)
Serpe, Loredana; Gallicchio, Margherita; Canaparo, Roberto; Dosio, Franco
PUB. DATE
January 2014
SOURCE
Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p31
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated with chemotherapy. Platinum-based drugs (cisplatin and carboplatin) comprise the core of first-line chemotherapy for patients with advanced ovarian cancer. Platinum-resistant ovarian cancer can be treated with cytotoxic chemotherapeutics such as paclitaxel, topotecan, PEGylated liposomal doxorubicin, or gemcitabine, but many patients eventually relapse on treatment. Targeted therapies based on agents specifically directed to overexpressed receptors, or to selected molecular targets, may be the future of clinical treatment. In this regard, overexpression of folate receptor-α on the surface of almost all epithelial ovarian cancers makes this receptor an excellent "tumor-associated antigen". With appropriate use of spacers/linkers, folate-targeted drugs can be distributed within the body, where they preferentially bind to ovarian cancer cells and are released inside their target cells. Here they can exert their desired cytotoxic function. Based on this strategy, 12 years after it was first described, a folate-targeted vinblastine derivative has now reached Phase III clinical trials in ovarian cancer. This review examines the importance of folate targeting, the state of the art of a vinblastine folate-targeted agent (vintafolide) for treating platinum-resistant ovarian cancer, and its diagnostic companion (etarfolatide) as a prognostic agent. Etarfolatide is a valuable noninvasive diagnostic imaging agent with which to select ovarian cancer patient populations that may benefit from this specific targeted therapy.
ACCESSION #
97595134

 

Related Articles

  • Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Dreyling, M.; Ghielmini, M.; Marcus, R.; Salles, G.; Vitolo, U.; Ladetto, M. // Annals of Oncology;Sep2014 Supplement, Vol. 25 Issue suppl_3, piii76 

    No abstract available.

  • Jejunal Metastasis Colliding With a Borderline Tumor in the Ovary. Piana, Simonetta; Giunta, Alessandro; Valli, Riccardo // International Journal of Surgical Pathology;Oct2015, Vol. 23 Issue 7, p567 

    Metastatic adenocarcinomas to the ovary can show morphologically innocuous areas simulating primary benign lesions or borderline tumors. Ruling out a metastasis can be a difficult issue for pathologists, especially when facing with cystic tumors. Because of the important clinical implications of...

  • Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells. Shengyun Cai; Pei Zhang; Suhe Dong; Li Li; Jianming Cai; Mingjuan Xu // Cellular Physiology & Biochemistry (Karger AG);Feb2018, Vol. 45 Issue 3, p1061 

    Background/Aims: Ovarian cancer (OC) is the fifth leading cause of cancer-related death in women, and it is difficult to diagnose at an early stage. The purpose of this study was to explore the prognostic biological markers of OC. Methods: Univariate Cox regression analysis was used to identify...

  • Pathway-Specific Engineered Mouse Allograft Models Functionally Recapitulate Human Serous Epithelial Ovarian Cancer. Szabova, Ludmila; Bupp, Sujata; Kamal, Muhaymin; Householder, Deborah B.; Hernandez, Lidia; Schlomer, Jerome J.; Baran, Maureen L.; Yi, Ming; Stephens, Robert M.; Annunziata, Christina M.; Martin, Philip L.; Van Dyke, Terry A.; Ohler, Zoe Weaver; Difilippantonio, Simone // PLoS ONE;Apr2014, Vol. 9 Issue 4, p1 

    The high mortality rate from ovarian cancers can be attributed to late-stage diagnosis and lack of effective treatment. Despite enormous effort to develop better targeted therapies, platinum-based chemotherapy still remains the standard of care for ovarian cancer patients, and resistance occurs...

  • A Clinicopathological Study of Malignant Ovarian Tumors in India. Garg, Ruchika; Singh, Saroj; Rani, Rekha; Agrawal, Mohita; Rajvanshi, Renu // Journal of the South Asian Federation of Menopause Societies;Jan-Jun2014, Vol. 2 Issue 1, p9 

    Ovarian cancer is the leading cause of death from gynecological cancer. Material and method: Surgical staging of all cases of ovarian cancer were done. Result and conclusion: Of the 50 cases of ovarian tumors operated 44% were malignant.duration of symptoms was 1 month or less in majority of...

  • Targeted therapies and clinical trials in ovarian cancer†. Dancey, J. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px59 

    Recent advances in molecular profiling have shown that cancers arising from the ovary are phenotypically and genetically heterogeneous. Within histologies, many mutations in druggable targets are uncommon in frequency but mutations leading to activation of specific signal transduction pathways...

  • Know warning signs for ovarian cancer. ELBENDARY, AL // South County Journal;3/20/2013, Vol. 48 Issue 12, pB2 

    In this article, the author suggests women to get diagnosed for ovarian cancer at an early stage for effective treatment.

  • The expression of platelet-activating factor receptor modulates the cisplatin sensitivity of ovarian cancer cells: a novel target for combination therapy. Yu, Y; Zhang, X; Hong, S; Zhang, M; Cai, Q; Jiang, W; Xu, C // British Journal of Cancer;7/29/2014, Vol. 111 Issue 3, p515 

    Background:Ovarian cancer has the highest mortality rate of the gynaecological cancers. Although cisplatin (CDDP) is an effective treatment for ovarian cancer, recurrence is frequent and leads to death. The objective was to explore the role and possible mechanisms of platelet-activating factor...

  • Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?  // Journal of Experimental & Clinical Cancer Research (17569966);2012, Vol. 31 Issue 1, p53 

    The article focuses on the role of histology-specific treatment for cell carcinoma of the ovary (CCC). It discusses the diagnosis, risks, staging procedures, and the treatment procedures for the treatment of CCC. It explores various interventions for CCC such as the administration of carboplatin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics